Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-Together: Sequential bepirovirsen followed by pegylated interferon alfa-2a in chronic hepatitis B
2020-002979-35Phase 2Unknown
- Sponsor
- GSK
- Start
- Nov 2020
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bepirovirsen in Chronic Hepatitis B (CHB) (2 arms), sponsored by GSK. Primary endpoint: Primary efficacy endpoint. Status: unknown.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2020-002979-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002979-35.